These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22508772)

  • 1. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
    Samrao A; Berry TM; Goreshi R; Simpson EL
    Arch Dermatol; 2012 Aug; 148(8):890-7. PubMed ID: 22508772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
    Volf EM; Au SC; Dumont N; Scheinman P; Gottlieb AB
    J Drugs Dermatol; 2012 Mar; 11(3):341-6. PubMed ID: 22395585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
    Simpson EL; Imafuku S; Poulin Y; Ungar B; Zhou L; Malik K; Wen HC; Xu H; Estrada YD; Peng X; Chen M; Shah N; Suarez-Farinas M; Pavel AB; Nograles K; Guttman-Yassky E
    J Invest Dermatol; 2019 May; 139(5):1063-1072. PubMed ID: 30528828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
    Strand V; Fiorentino D; Hu C; Day RM; Stevens RM; Papp KA
    Health Qual Life Outcomes; 2013 May; 11():82. PubMed ID: 23663752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.
    Furue M; Kitahara Y; Akama H; Hojo S; Hayashi N; Nakagawa H;
    J Dermatol; 2014 Jul; 41(7):577-85. PubMed ID: 24942594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast for psoriasis treatment.
    Carrascosa JM; Del-Alcazar E
    G Ital Dermatol Venereol; 2020 Aug; 155(4):421-433. PubMed ID: 32545946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
    Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
    J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
    JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
    Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
    J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J; Liao W
    Dermatol Online J; 2017 May; 23(5):. PubMed ID: 28537861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
    Kabashima K; Matsumura T; Komazaki H; Kawashima M;
    N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
    Simpson EL; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Ständer S; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
    Acta Derm Venereol; 2019 Jul; 99(9):756-761. PubMed ID: 30896779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
    Moustafa F; Feldman SR
    Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-centre prospective study comparing efficacy and safety of apremilast with cyclosporine in moderate to severe atopic dermatitis.
    Vyas HR; Shah SR; Shah BJ; Parmar KS; Jangid N; Choudhary A; Gehlawat T; Mistry D
    Australas J Dermatol; 2023 Nov; 64(4):e333-e339. PubMed ID: 37488939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
    Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
    G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.